0001672688-26-000136 | 10-Q | XBRL Viewer

Print Document

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash Flows From Operating Activities
Net loss	$ (62,809)	$ (56,915)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	5,424	6,072
Stock-based compensation	9,621	9,666
Accretion of discount on marketable securities	(749)	(1,368)
Other	(487)	(119)
Changes in operating assets and liabilities:
Accounts receivable, net	0	(700)
Prepaid expenses and other current assets	(1,720)	1,860
Operating lease right-of-use assets and liabilities	(278)	(268)
Other long-term assets	0	(86)
Accounts payable and accrued expenses	(3,091)	3,308
Deferred revenue	218	(162)
Net cash used in operating activities	(53,871)	(38,712)
Cash Flows From Investing Activities
Purchases of property and equipment	(31)	(248)
Investment in marketable securities	(22,573)	(57,940)
Proceeds from maturities of marketable securities	53,988	51,000
Proceeds from sales of property and equipment	46	1,183
Net cash provided by (used in) investing activities	31,430	(6,005)
Cash Flows From Financing Activities
Principal payments on long-term debt	(723)	(1,843)
Principal payments on finance lease obligations	0	(72)
Proceeds from issuance of common stock, net	106,099	41,689
Proceeds from issuance of common stock through employee equity plans, net	4,906	2,016
Net cash provided by financing activities	110,282	41,790
Net increase (decrease) in cash, cash equivalents, and restricted cash	87,841	(2,927)
Cash, cash equivalents and restricted cash - Beginning of period	21,078	58,214
Cash, cash equivalents, and restricted cash - End of period	$ 108,919	$ 55,287

Revenue recognition	6 Months Ended
Revenue recognition	Jun. 30, 2026
Revenue from Contract with Customer [Abstract]
Revenue recognition	Revenue recognition Contract balances Contract assets are generated when contractual billing schedules differ from revenue recognition timing and the Company records a contract asset when it has a conditional right to consideration. As of June 30, 2026 contract assets were $0.3 million. Contract liabilities are recorded as deferred revenue when cash payments are received or due in advance of the satisfaction of performance obligations. As of June 30, 2026 and December 31, 2025, contract liabilities were $1.4 million and $1.2 million, respectively. During the three and six months ended June 30, 2026, the Company recognized $0.3 million and $0.5 million, respectively, as revenue that had been included in deferred revenue at the beginning of the period. During the three and six months ended June 30, 2025, the Company recognized $0.2 million and $0.6 million, respectively, as revenue that had been included in deferred revenue at the beginning of the period. The Company expects the remaining contract liabilities to be recognized as revenue between one to two years. Concentration of risk During the three and six months ended June 30, 2026, three partners represented 100% of total partner program revenue. During the three months ended June 30, 2025, two partners represented approximately 99% of total partner program revenue. During the six months ended June 30, 2025, three partners represented 100% of total partner program revenue. For the three and six months ended June 30, 2026 and 2025, substantially all partner program revenue was attributable to foreign partners.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

+ Details

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenues
Partner program revenue	$ 318	$ 593	$ 533	$ 1,772
Operating expenses
Research and development	22,616	20,458	41,891	36,822
Selling, general and administrative	9,164	8,528	18,222	18,000
Depreciation and amortization	2,696	3,000	5,424	6,072
Total operating expenses	34,476	31,986	65,537	60,894
Operating loss	(34,158)	(31,393)	(65,004)	(59,122)
Other income (expense)
Interest expense	(2)	(56)	(20)	(135)
Other income, net	990	1,011	2,273	2,469
Total other income, net	988	955	2,253	2,334
Loss before income taxes	(33,170)	(30,438)	(62,751)	(56,788)
Income tax expense	(40)	(131)	(58)	(127)
Net loss	$ (33,210)	$ (30,569)	$ (62,809)	$ (56,915)
Net loss per share: basic (in usd per share)	$ (0.21)	$ (0.24)	$ (0.40)	$ (0.45)
Net loss per share: diluted (in usd per share)	$ (0.21)	$ (0.24)	$ (0.40)	$ (0.45)
Weighted-average common shares outstanding: basic (in shares)	157,471,712	127,592,948	155,217,585	126,035,844
Weighted-average common shares outstanding: diluted (in shares)	157,471,712	127,592,948	155,217,585	126,035,844
Comprehensive loss:
Net loss	$ (33,210)	$ (30,569)	$ (62,809)	$ (56,915)
Foreign currency translation adjustments	(52)	324	(117)	401
Unrealized loss on marketable securities	(102)	(32)	(324)	(86)
Comprehensive loss	$ (33,364)	$ (30,277)	$ (63,250)	$ (56,600)
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]			License and Service [Member]

Stock-based compensation (Tables)

6 Months Ended

Jun. 30, 2026

Share-Based Payment Arrangement [Abstract]

Schedule of Allocation of Share-based Compensation

Total stock-based compensation expense related to the Company’s stock-based awards was recorded in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):



	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2026		2025			2026		2025
Research and development	$	2,332	$	2,015		$	4,346	$	4,038
Selling, general and administrative	2,913		2,737			5,279		5,659
Total stock-based compensation expense	$	5,245	$	4,752		$	9,625	$	9,697

Schedule of Stock Option Activity

Activity for stock options is shown below:


	Number of Options	Weighted Average Exercise Price per Share		Weighted Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value (in thousands $)
Outstanding at December 31, 2025	20,716,511	$	3.27	7.5
Granted	6,620,200	3.16
Exercised	(2,260,119)	2.76			6,330
Canceled/Forfeited	(1,876,559)	3.10
Expired	(59,622)	7.80
Outstanding at June 30, 2026	23,140,411	3.29		7.9	192,964
Exercisable at June 30, 2026	11,371,137	$	3.44	6.7	$	93,578

Schedule of Non-vested Share Activity

Activity for restricted stock units is shown below:


	Number of Shares	Weighted Average Grant Date Fair Value
Unvested as of December 31, 2025	3,789,634	$	3.32
Granted	2,179,050	3.02
Vested	(934,358)	3.49
Forfeitures	(529,658)	2.91
Unvested as of June 30, 2026	4,504,668	$	3.18

Fair value measurements (Tables)

6 Months Ended

Jun. 30, 2026

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following tables summarize the Company’s assets and liabilities measured at fair value on a recurring basis as of June 30, 2026 and December 31, 2025 (in thousands):



	June 30, 2026
	Level 1		Level 2		Level 3		Total
Assets:
Debt Securities:
Money market funds	$	98,399	$	—	$	—	$	98,399

U.S. treasuries	—		93,277		—		93,277


Total assets	$	98,399	$	93,277	$	—	$	191,676



	December 31, 2025
	Level 1		Level 2		Level 3		Total
Assets
Debt Securities:
Money market funds	$	14,410	$	—	$	—	$	14,410

U.S. treasuries	6,873		117,394		—		124,267


Total assets	$	21,283	$	117,394	$	—	$	138,677

Segment reporting - Narrative (Details)	6 Months Ended
Segment reporting - Narrative (Details)	Jun. 30, 2026 segment
Segment Reporting [Abstract]
Number of reportable segments	1

Net loss per share (Tables)

6 Months Ended

Jun. 30, 2026

Earnings Per Share [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following potentially dilutive securities, presented based on amounts outstanding at period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders because including them would be anti-dilutive:



	For the Six Months Ended June 30,
		2026	2025

Stock options		23,140,411	21,405,586
Restricted stock units		4,504,668	4,403,002

Employee stock purchase plan		80,616	106,587
Total		27,725,695	25,915,175

Stock-based compensation - Stock Option Rollforward (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2026	Dec. 31, 2025
Number of Options
Beginning balance (in shares)	20,716,511
Granted (in shares)	6,620,200
Exercised (in shares)	(2,260,119)
Canceled/Forfeited (in shares)	(1,876,559)
Expired (in shares)	(59,622)
Ending balance (in shares)	23,140,411	20,716,511
Exercisable (in shares)	11,371,137
Weighted Average Exercise Price per Share
Beginning balance (in usd per share)	$ 3.27
Granted (in usd per share)	3.16
Exercised (in usd per share)	2.76
Canceled/Forfeited (in usd per share)	3.10
Expired (in usd per share)	7.80
Ending balance (in usd per share)	3.29	$ 3.27
Exercisable, weighted average price (in usd per share)	$ 3.44
Weighted Average Remaining Contractual Term (in years)	7 years 10 months 24 days	7 years 6 months
Exercisable, weighted average remaining contractual term (in years)	6 years 8 months 12 days
Intrinsic value, shares outstanding	$ 192,964
Intrinsic value, exercised	6,330
Exercisable, aggregate intrinsic value	$ 93,578

Investments - Amortized and Fair Value of our Investments (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Assets
Amortized cost	$ 191,793	$ 138,469
Gross unrealized gains	8	208
Gross unrealized losses	(125)	0
Fair market value	191,676	138,677
Cash equivalents
Assets
Fair market value	98,399	14,410
Marketable securities
Assets
Fair market value	93,277	124,267
Money market funds
Assets
Amortized cost	98,399	14,410
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Fair market value	98,399	14,410
U.S. treasuries
Assets
Amortized cost	93,394	124,059
Gross unrealized gains	8	208
Gross unrealized losses	(125)	0
Fair market value	$ 93,277	$ 124,267

Summary of significant accounting policies	6 Months Ended
Summary of significant accounting policies	Jun. 30, 2026
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies Basis of presentation The condensed consolidated financial statements are prepared in accordance with U.S. GAAP as defined by the Financial Accounting Standards Board (“FASB”). The condensed consolidated financial statements include the Company’s wholly-owned subsidiaries and entities under its control. The Company has eliminated all intercompany transactions and accounts. There have been no material changes in the accounting policies from those disclosed in the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on March 24, 2026.

Stock-based compensation

6 Months Ended

Jun. 30, 2026

Share-Based Payment Arrangement [Abstract]

Stock-based compensation

The Company grants stock options, restricted stock units, and stock appreciation rights (“SARs”) under the 2021 Stock Option and Incentive Plan (“2021 Plan”) and the 2023 Inducement Plan (the “2023 Inducement Plan”). On January 1, 2026, the number of shares of common stock reserved for future issuance under the 2021 Plan was increased by 7,575,754 shares pursuant to an automatic annual increase. As of June 30, 2026, 8,805,878 shares were available for issuance under the 2021 Plan. As of June 30, 2026, 798,000 shares were available for issuance under the 2023 Inducement Plan.



	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2026		2025			2026		2025
Research and development	$	2,332	$	2,015		$	4,346	$	4,038
Selling, general and administrative	2,913		2,737			5,279		5,659
Total stock-based compensation expense	$	5,245	$	4,752		$	9,625	$	9,697

Stock Options

Stock options generally vest 25% after one year from the date of the grant with the remainder vesting monthly over the following three-year period or ratably over three years in three equal installments. The Company recognizes forfeitures as they occur and uses the straight-line expense recognition method. Activity for stock options is shown below:


	Number of Options	Weighted Average Exercise Price per Share		Weighted Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value (in thousands $)
Outstanding at December 31, 2025	20,716,511	$	3.27	7.5
Granted	6,620,200	3.16
Exercised	(2,260,119)	2.76			6,330
Canceled/Forfeited	(1,876,559)	3.10
Expired	(59,622)	7.80
Outstanding at June 30, 2026	23,140,411	3.29		7.9	192,964
Exercisable at June 30, 2026	11,371,137	$	3.44	6.7	$	93,578

As of June 30, 2026, total unrecognized stock-based compensation related to stock options was $24.4 million, which the Company expects to recognize over a remaining weighted average period of 2.3 years.

Restricted stock units

Restricted stock units subject to time-based vesting generally vest over a term of 1-4 years. The Company recognizes forfeitures as they occur and uses the straight-line expense recognition method. Activity for restricted stock units is shown below:


	Number of Shares	Weighted Average Grant Date Fair Value
Unvested as of December 31, 2025	3,789,634	$	3.32
Granted	2,179,050	3.02
Vested	(934,358)	3.49
Forfeitures	(529,658)	2.91
Unvested as of June 30, 2026	4,504,668	$	3.18

As of June 30, 2026, there was $7.7 million of unrecognized compensation expense related to the outstanding restricted stock units expected to be recognized over a remaining weighted-average period of 2.2 years.

Restricted stock unit award with market conditions

In March 2024, the Company granted 1,500,000 performance restricted stock units to its Founder and Chief Executive Officer that contained market conditions (the “2024 Market Award”). Subject to the holder’s continued service, the 2024 Market Award provided for vesting in tranches once the Company’s closing stock price meets or exceeds certain thresholds established by the Company’s Compensation Committee of the Board of Directors. The original grant-date fair value of the 2024 Market Award of $5.5 million was determined using a Monte Carlo simulation model using an expected volatility of 97% and risk-free rate of 4.5%. The stock-based compensation expense was recognized over the derived service period for each tranche over periods up to 1.3 years. As of June 30, 2026, the stock price threshold of $10.00 for the 2024 Market Award had been met resulting in 150,000 shares vesting. Any unvested tranches of the 2024 Market Award will expire in March 2027 if the vesting conditions are not met.

Revenue recognition (Details) $ in Millions	3 Months Ended		6 Months Ended
Revenue recognition (Details) $ in Millions	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($) partner	Jun. 30, 2026 USD ($) partner	Jun. 30, 2025 USD ($) partner	Dec. 31, 2025 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative
Contract assets	$ 0.3		$ 0.3
Contract liabilities	1.4		1.4		$ 1.2
Revenue recognized from customer contract liability	$ 0.3	$ 0.2	$ 0.5	$ 0.6
Minimum
Collaborative Arrangement and Arrangement Other than Collaborative
Revenue, remaining performance obligation, expected timing of satisfaction, period (in years)	1 year		1 year
Maximum
Collaborative Arrangement and Arrangement Other than Collaborative
Revenue, remaining performance obligation, expected timing of satisfaction, period (in years)	2 years		2 years
Partner program revenue \| Revenue from Contract with Customer Benchmark \| Customer Concentration Risk
Collaborative Arrangement and Arrangement Other than Collaborative
Number of partners (partner) \| partner		2	3	3
Concentration risk (as a percent)		99.00%	100.00%	100.00%

Investments (Tables)

6 Months Ended

Jun. 30, 2026

Cash and Cash Equivalents [Abstract]

Schedule of Amortized and Fair Value of Our Investments

The amortized cost and fair value of investments are as follows (in thousands):



	June 30, 2026
	Amortized cost		Gross unrealized gains		Gross unrealized losses		Fair market value
Assets
Money market funds	$	98,399	$	—	$	—	$	98,399

U.S. treasuries	93,394		8		(125)		93,277
Total	$	191,793	$	8	$	(125)	$	191,676
Classified as:
Cash equivalents							$	98,399
Marketable securities							93,277

Total							$	191,676



	December 31, 2025
	Amortized cost		Gross unrealized gains		Gross unrealized losses		Fair market value
Assets
Money market funds	$	14,410	$	—	$	—	$	14,410

U.S. treasuries	124,059		208		—		124,267
Total	$	138,469	$	208	$	—	$	138,677
Classified as:
Cash equivalents							$	14,410
Marketable securities							124,267

Total							$	138,677

Stock-based compensation - Narratives (Details) $ / shares in Units, $ in Millions		1 Months Ended	6 Months Ended
	Jan. 01, 2026 shares	Mar. 31, 2024 USD ($) shares	Jun. 30, 2026 USD ($) installment $ / shares shares
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award
Share based compensation expense not yet recognized, recognition period (in years)			2 years 2 months 12 days
Share based compensation expense not yet recognized other than options \| $			$ 7.7
Granted (in usd per share) \| $ / shares			$ 3.02
Granted (in shares)			2,179,050
Restricted stock units \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period (in years)			1 year
Restricted stock units \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period (in years)			4 years
Restricted stock award with market conditions
Share-based Compensation Arrangement by Share-based Payment Award
Share based compensation expense not yet recognized, recognition period (in years)		1 year 3 months 18 days
Granted (in shares)		1,500,000
Grant-date fair value \| $		$ 5.5
Volatility rate (as a percent)		97.00%
Risk-free interest rate		4.50%
Stock price threshold (in dollars per share) \| $ / shares			$ 10.00
Vesting (in shares)			150,000
2021 Plan
Share-based Compensation Arrangement by Share-based Payment Award
Additional shares authorized for issuance (in shares)	7,575,754
Shares available for grant (in shares)			8,805,878
2023 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award
Shares available for employee (in shares)			798,000
2020 Plan \| Stock options
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period (in years)			3 years
Number of installment payments (installment) \| installment			3
Share based compensation expense not yet recognized, options \| $			$ 24.4
Share based compensation expense not yet recognized, recognition period (in years)			2 years 3 months 18 days
2020 Plan \| Stock options \| Vest On Closing
Share-based Compensation Arrangement by Share-based Payment Award
Vesting percentage (as a percent)			25.00%
Vesting period (in years)			1 year
2020 Plan \| Stock options \| Share Vesting Based On Service
Share-based Compensation Arrangement by Share-based Payment Award
Vesting percentage (as a percent)			25.00%
2020 Plan \| Stock options \| Tranche Three
Share-based Compensation Arrangement by Share-based Payment Award
Vesting percentage (as a percent)			25.00%
2020 Plan \| Stock options \| Tranche Four
Share-based Compensation Arrangement by Share-based Payment Award
Vesting percentage (as a percent)			25.00%

UNAUDITED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)
Beginning balance (in shares) at Dec. 31, 2024		115,362,265
Beginning balance at Dec. 31, 2024	$ 179,133	$ 12	$ 688,726	$ (509,601)	$ (4)
Increase (Decrease) in Stockholders' Equity
Issuance of common shares, net of issuance costs (in shares)		10,983,477
Issuance of common shares, net of issuance costs	39,159	$ 1	39,158
Issuance of shares under stock plans, net of shares withheld for tax payments (in shares)		1,195,012
Issuance of shares under stock plans, net of shares withheld for tax payments	1,914		1,914
Stock-based compensation	4,913		4,913
Foreign currency translation adjustments	77				77
Unrealized loss on marketable securities	(54)				(54)
Net loss	(26,346)			(26,346)
Ending balance (in shares) at Mar. 31, 2025		127,540,754
Ending balance at Mar. 31, 2025	198,796	$ 13	734,711	(535,947)	19
Beginning balance (in shares) at Dec. 31, 2024		115,362,265
Beginning balance at Dec. 31, 2024	179,133	$ 12	688,726	(509,601)	(4)
Increase (Decrease) in Stockholders' Equity
Foreign currency translation adjustments	401
Unrealized loss on marketable securities	(86)
Net loss	(56,915)
Ending balance (in shares) at Jun. 30, 2025		127,677,180
Ending balance at Jun. 30, 2025	173,373	$ 13	739,565	(566,516)	311
Beginning balance (in shares) at Mar. 31, 2025		127,540,754
Beginning balance at Mar. 31, 2025	198,796	$ 13	734,711	(535,947)	19
Increase (Decrease) in Stockholders' Equity
Issuance of shares under stock plans, net of shares withheld for tax payments (in shares)		136,426
Issuance of shares under stock plans, net of shares withheld for tax payments	102		102
Stock-based compensation	4,752		4,752
Foreign currency translation adjustments	324				324
Unrealized loss on marketable securities	(32)				(32)
Net loss	(30,569)			(30,569)
Ending balance (in shares) at Jun. 30, 2025		127,677,180
Ending balance at Jun. 30, 2025	173,373	$ 13	739,565	(566,516)	311
Beginning balance (in shares) at Dec. 31, 2025		151,515,079
Beginning balance at Dec. 31, 2025	189,449	$ 15	813,627	(624,784)	591
Increase (Decrease) in Stockholders' Equity
Issuance of common shares, net of issuance costs (in shares)		2,871,218
Issuance of common shares, net of issuance costs	7,957		7,957
Issuance of shares under stock plans, net of shares withheld for tax payments (in shares)		963,838
Issuance of shares under stock plans, net of shares withheld for tax payments	59		59
Stock-based compensation	4,392		4,392
Foreign currency translation adjustments	(65)				(65)
Unrealized loss on marketable securities	(222)				(222)
Net loss	(29,599)			(29,599)
Ending balance (in shares) at Mar. 31, 2026		155,350,135
Ending balance at Mar. 31, 2026	171,971	$ 15	826,035	(654,383)	304
Beginning balance (in shares) at Dec. 31, 2025		151,515,079
Beginning balance at Dec. 31, 2025	189,449	$ 15	813,627	(624,784)	591
Increase (Decrease) in Stockholders' Equity
Foreign currency translation adjustments	(117)
Unrealized loss on marketable securities	(324)
Net loss	(62,809)
Ending balance (in shares) at Jun. 30, 2026		171,558,470
Ending balance at Jun. 30, 2026	246,131	$ 17	933,557	(687,593)	150
Beginning balance (in shares) at Mar. 31, 2026		155,350,135
Beginning balance at Mar. 31, 2026	171,971	$ 15	826,035	(654,383)	304
Increase (Decrease) in Stockholders' Equity
Issuance of common shares, net of issuance costs (in shares)		14,286,305
Issuance of common shares, net of issuance costs	98,142	$ 2	98,140
Issuance of shares under stock plans, net of shares withheld for tax payments (in shares)		1,922,030
Issuance of shares under stock plans, net of shares withheld for tax payments	4,847		4,847
Stock-based compensation	4,535		4,535
Foreign currency translation adjustments	(52)				(52)
Unrealized loss on marketable securities	(102)				(102)
Net loss	(33,210)			(33,210)
Ending balance (in shares) at Jun. 30, 2026		171,558,470
Ending balance at Jun. 30, 2026	$ 246,131	$ 17	$ 933,557	$ (687,593)	$ 150

Fair value measurements - Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Assets:
Debt Securities:	$ 191,676	$ 138,677
Total assets	191,676	138,677
Money market funds
Assets:
Debt Securities:	98,399	14,410
U.S. treasuries
Assets:
Debt Securities:	93,277	124,267
Level 1
Assets:
Total assets	98,399	21,283
Level 1 \| Money market funds
Assets:
Debt Securities:	98,399	14,410
Level 1 \| U.S. treasuries
Assets:
Debt Securities:	0	6,873
Level 2
Assets:
Total assets	93,277	117,394
Level 2 \| Money market funds
Assets:
Debt Securities:	0	0
Level 2 \| U.S. treasuries
Assets:
Debt Securities:	93,277	117,394
Level 3
Assets:
Total assets	0	0
Level 3 \| Money market funds
Assets:
Debt Securities:	0	0
Level 3 \| U.S. treasuries
Assets:
Debt Securities:	$ 0	$ 0

Net loss per share

6 Months Ended

Jun. 30, 2026

Earnings Per Share [Abstract]

Net loss per share

Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period.

The common stock issuable upon the conversion or exercise of the following dilutive securities has been excluded from the diluted net loss per share calculation because their effect would have been anti-dilutive. Diluted net loss per share, therefore, does not differ from basic net loss per share for the periods presented.



	For the Six Months Ended June 30,
		2026	2025

Stock options		23,140,411	21,405,586
Restricted stock units		4,504,668	4,403,002

Employee stock purchase plan		80,616	106,587
Total		27,725,695	25,915,175

Accounts payable and accrued expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Accounts Payable and Accrued Liabilities [Abstract]
Accounts payable	$ 7,156	$ 2,756
Accrued compensation	3,471	6,615
Accrued preclinical and clinical development expenses	1,835	6,350
Accrued other	3,795	3,627
Total accounts payable and accrued expenses	$ 16,257	$ 19,348

Segment reporting - Segment Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Segment Reporting
Research and development expense	$ 22,616	$ 20,458	$ 41,891	$ 36,822
Stock-based compensation	5,245	4,752	9,625	9,697
Depreciation and amortization	2,696	3,000	5,424	6,072
Total operating expenses	34,476	31,986	65,537	60,894
Segment One
Segment Reporting
Personnel	9,569	10,283	18,815	20,148
Stock-based compensation	5,245	4,752	9,625	9,697
General & administrative	4,032	3,538	8,366	7,860
Depreciation and amortization	2,696	3,000	5,424	6,072
Other (gain)/loss, net	37	(246)	40	(232)
Total operating expenses	34,476	31,986	65,537	60,894
Drug creation program and platform \| Segment One
Segment Reporting
Research and development expense	6,045	5,289	12,128	9,295
External preclinical and clinical development \| Segment One
Segment Reporting
Research and development expense	$ 6,852	$ 5,370	$ 11,139	$ 8,054

UNAUDITED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (Parenthetical) $ in Thousands	3 Months Ended
	Jun. 30, 2026 USD ($)
Statement of Stockholders' Equity [Abstract]
Stock issuance costs	$ 400

Accounts payable and accrued expenses

6 Months Ended

Jun. 30, 2026

Accounts Payable and Accrued Liabilities [Abstract]

Accounts payable and accrued expenses

Total accounts payable and accrued expenses reported on the condensed consolidated balance sheets as follows (in thousands):



	June 30,		December 31,
	2026		2025
Accounts payable	$	7,156	2,756
Accrued compensation	3,471		6,615
Accrued preclinical and clinical development expenses	1,835		6,350
Accrued other	3,795		3,627


Total accounts payable and accrued expenses	$	16,257	$	19,348

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Jun. 30, 2026
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Accounts payable and accrued expenses (Tables)

6 Months Ended

Jun. 30, 2026

Accounts Payable and Accrued Liabilities [Abstract]

Schedule of Accounts payable and accrued expenses

Total accounts payable and accrued expenses reported on the condensed consolidated balance sheets as follows (in thousands):



	June 30,		December 31,
	2026		2025
Accounts payable	$	7,156	2,756
Accrued compensation	3,471		6,615
Accrued preclinical and clinical development expenses	1,835		6,350
Accrued other	3,795		3,627


Total accounts payable and accrued expenses	$	16,257	$	19,348

Investments - Narratives (Details) - USD ($)	6 Months Ended
Investments - Narratives (Details) - USD ($)	Jun. 30, 2026	Jun. 30, 2025
Cash and Cash Equivalents [Abstract]
Marketable securities, noncurrent	$ 0
Realized gain (loss)	$ 0	$ 0

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 107,865	$ 20,025
Marketable securities	93,277	124,267
Prepaid expenses and other current assets	7,124	5,281
Total current assets	208,266	149,573
Operating lease right-of-use assets	2,442	2,914
Property and equipment, net	16,721	20,860
Intangibles, net	40,051	41,514
Restricted cash, long-term	1,054	1,053
Other long-term assets	383	383
TOTAL ASSETS	268,917	216,297
Current liabilities:
Accounts payable and accrued expenses	16,257	19,348
Long-term debt	150	873
Operating lease obligations	2,037	1,805
Deferred revenue	1,154	739
Total current liabilities	19,598	22,765
Operating lease obligations, net of current portion	1,642	2,624
Deferred revenue, long-term	240	436
Other long-term liabilities	1,306	1,023
TOTAL LIABILITIES	22,786	26,848
STOCKHOLDERS' EQUITY
Preferred stock	0	0
Common stock	17	15
Additional paid-in capital	933,557	813,627
Accumulated deficit	(687,593)	(624,784)
Accumulated other comprehensive income	150	591
TOTAL STOCKHOLDERS' EQUITY	246,131	189,449
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 268,917	$ 216,297

Segment reporting (Tables)

6 Months Ended

Jun. 30, 2026

Segment Reporting [Abstract]

Segment Reporting

The table below is a summary of the significant segment expenses (in thousands) provided to the Company’s CODM on a regular basis:



	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Drug creation programs and platform (1)	$	6,045	$	5,289	$	12,128	$	9,295
External preclinical and clinical development (2)	6,852		5,370		11,139		8,054
Personnel (3)	9,569		10,283		18,815		20,148
Stock-based compensation	5,245		4,752		9,625		9,697
General & administrative	4,032		3,538		8,366		7,860
Depreciation and amortization	2,696		3,000		5,424		6,072
Other (gain)/loss, net (4)	37		(246)		40		(232)
Total operating expenses	$	34,476	$	31,986	$	65,537	$	60,894

(1) “Drug creation programs and platform” consists of research and development costs incurred related to the Company’s internally developed programs and drug creation partnership programs for activities prior to the nomination of a development candidate and the continued development of the Company’s Integrated Drug Creation platform.

(2) “External preclinical and clinical development” expense consists of external costs incurred following the Company’s nomination of a development candidate, including all subsequent contract research services, contract manufacturing, consulting fees, and other external costs related to preclinical and clinical development.

(3) “Personnel” expense consists of all employee wages, taxes, benefits, severance, and other employee related costs.

(4) “Other (gain)/loss, net” consists of non-routine gains and losses.

- Definition

Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

+ Details

Organization and nature of operations	6 Months Ended
Organization and nature of operations	Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and nature of operations	Organization and nature of operations Absci Corporation (the “Company”) is a clinical-stage biopharmaceutical company using an AI-native approach to develop differentiated antibody-based therapeutics. The Company was organized in the State of Oregon in August 2011 as a limited liability company and converted to a limited liability company (“LLC”) in Delaware in April 2016. In October 2020, the Company converted from a Delaware LLC to a Delaware corporation. The Company’s headquarters are located in Vancouver, Washington. Unaudited interim financial information The Company prepared its interim condensed consolidated financial statements that accompany these notes in conformity with accounting principles generally accepted in the United States, consistent in all material respects with those applied in its Annual Report on Form 10-K for the year ended December 31, 2025. The Company has made estimates and judgments affecting the amounts reported in its condensed consolidated financial statements and the accompanying notes. The actual results that the Company experiences may differ materially from its estimates. The interim financial information is unaudited and reflects all normal adjustments that are, in the Company’s opinion, necessary to provide a fair statement of results for the interim periods presented. This report should be read in conjunction with the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.

Net loss per share - Anti-dilutive Securities (Details) - shares	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Antidilutive Securities Excluded from Computation of Earnings Per Share
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	27,725,695	25,915,175
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	23,140,411	21,405,586
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	4,504,668	4,403,002
Employee stock purchase plan
Antidilutive Securities Excluded from Computation of Earnings Per Share
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	80,616	106,587

Common stock	6 Months Ended
Common stock	Jun. 30, 2026
Equity [Abstract]
Common stock	Common stock Public offering of common stock In June 2026, the Company sold an aggregate of 13,495,277 shares of its common stock pursuant to an underwriting agreement with Jefferies LLC, J.P. Morgan Securities LLC, TD Securities (USA) LLC, and Guggenheim Securities LLC, at a public offering price of $7.41 per share. The Company received total net proceeds from the offering of approximately $93.6 million after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. At-the-market offering In August 2025, the Company entered into a Sales Agreement with TD Securities (USA) LLC, as Sales Agent (the “Sales Agreement”), with respect to an “at the market offering” program under which the Company may offer and sell, from time to time, shares of its common stock having an aggregate offering price of up to $100.0 million through the Sales Agent. The Company has agreed to pay the Sales Agent a commission of up to 3.0% of the gross proceeds of any shares sold under the Sales Agreement. Upon execution, the Sales Agreement terminated and superseded the prior sales agreement entered into in June 2023 in its entirety. During the six months ended June 30, 2026, the Company issued and sold 3,662,246 shares and received $12.5 million in net proceeds from the sale of securities pursuant to the Sales Agreement. Private investment in public equity In January 2025, the Company entered into a strategic collaboration with Advanced Micro Devices, Inc. (AMD) and sold an aggregate of 5,714,285 shares of the Company’s common stock to AMD for net proceeds of $20.0 million through a private investment in public equity (PIPE). This strategic collaboration with AMD has a goal to optimize the performance of AMD InstinctTM accelerators and ROCmTM software to support the Company’s AI drug creation, including its de novo antibody design models. The issuance of stock to AMD was at a premium of approximately $2.5 million over the market price on the issuance date. The premium was recorded to accrued expenses and other long-term liabilities on the condensed consolidated balance sheet and will be recognized as a credit to research and development expense over the collaboration term. The amortization of the premium was $0.4 million for the six months ended June 30, 2026.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479951/505-20-S50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479982/505-20-S25-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479951/505-20-S50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S25
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479982/505-20-S25-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481520/505-30-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 1.D.2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479921/505-20-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479951/505-20-S50-3

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 1.B.3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480148/855-10-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S25
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479982/505-20-S25-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-5

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

+ Details

Stock-based compensation - Allocated Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Share-based Payment Arrangement, Expensed
Total stock-based compensation expense	$ 5,245	$ 4,752	$ 9,625	$ 9,697
Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense
Share-based Payment Arrangement, Expensed
Total stock-based compensation expense	2,913	2,737	5,279	5,659
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense
Share-based Payment Arrangement, Expensed
Total stock-based compensation expense	$ 2,332	$ 2,015	$ 4,346	$ 4,038

Segment reporting

6 Months Ended

Jun. 30, 2026

Segment Reporting [Abstract]

Segment reporting

The Company has one reportable segment.

The Company’s Chief Operating Decision Maker (the “CODM”), its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating performance. When evaluating the Company’s financial performance, the CODM regularly reviews total expenses by expense category and the CODM makes decisions using this information on a consolidated basis. There are no other measures of profitability used by the CODM, other than those disclosed in these condensed consolidated financial statements.

The table below is a summary of the significant segment expenses (in thousands) provided to the Company’s CODM on a regular basis:



	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Drug creation programs and platform (1)	$	6,045	$	5,289	$	12,128	$	9,295
External preclinical and clinical development (2)	6,852		5,370		11,139		8,054
Personnel (3)	9,569		10,283		18,815		20,148
Stock-based compensation	5,245		4,752		9,625		9,697
General & administrative	4,032		3,538		8,366		7,860
Depreciation and amortization	2,696		3,000		5,424		6,072
Other (gain)/loss, net (4)	37		(246)		40		(232)
Total operating expenses	$	34,476	$	31,986	$	65,537	$	60,894

(3) “Personnel” expense consists of all employee wages, taxes, benefits, severance, and other employee related costs.

(4) “Other (gain)/loss, net” consists of non-routine gains and losses.

- Definition

The entire disclosure for segment reporting.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 18: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 19: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 21: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

+ Details

Summary of significant accounting policies (Policies)	6 Months Ended
Summary of significant accounting policies (Policies)	Jun. 30, 2026
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The condensed consolidated financial statements are prepared in accordance with U.S. GAAP as defined by the Financial Accounting Standards Board (“FASB”). The condensed consolidated financial statements include the Company’s wholly-owned subsidiaries and entities under its control. The Company has eliminated all intercompany transactions and accounts. There have been no material changes in the accounting policies from those disclosed in the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on March 24, 2026.

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2026	Jul. 31, 2026
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2026
Document Transition Report	false
Entity File Number	001-40646
Entity Registrant Name	ABSCI CORP
Entity Incorporation, State	DE
Entity Tax Identification Number	85-3383487
Entity Address, Street	18105 SE Mill Plain Blvd
Entity Address, City	Vancouver
Entity Address, State	WA
Entity Address, Postal Zip Code	98683
City Area Code	360
Local Phone Number	949-1041
Title of each class	Common Stock. $0.0001 par value
Trading Symbol(s)	ABSI
Name of each exchange on which registered	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		171,614,010
Amendment Flag	false
Current Fiscal Year End	--12-31
Document Fiscal Year Focus	2026
Document Fiscal Period Focus	Q2
CIK	0001672688

Investments

6 Months Ended

Jun. 30, 2026

Cash and Cash Equivalents [Abstract]

Investments

Cash equivalents and marketable securities are classified as available-for-sale and are recorded at fair value on the condensed consolidated balance sheets, with any unrealized gains and losses reported in accumulated other comprehensive loss, which is reflected as a separate component of stockholders’ equity on the Company’s condensed consolidated balance sheets, until realized. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company considers all marketable securities to be current assets as they are available for use in current operations.

The amortized cost and fair value of investments are as follows (in thousands):



	June 30, 2026
	Amortized cost		Gross unrealized gains		Gross unrealized losses		Fair market value
Assets
Money market funds	$	98,399	$	—	$	—	$	98,399

U.S. treasuries	93,394		8		(125)		93,277
Total	$	191,793	$	8	$	(125)	$	191,676
Classified as:
Cash equivalents							$	98,399
Marketable securities							93,277

Total							$	191,676



	December 31, 2025
	Amortized cost		Gross unrealized gains		Gross unrealized losses		Fair market value
Assets
Money market funds	$	14,410	$	—	$	—	$	14,410

U.S. treasuries	124,059		208		—		124,267
Total	$	138,469	$	208	$	—	$	138,677
Classified as:
Cash equivalents							$	14,410
Marketable securities							124,267

Total							$	138,677

As of June 30, 2026, the Company held no marketable securities with a remaining maturity of greater than one year. There were no realized gains or losses on securities for the six months ended June 30, 2026 and 2025. Unrealized gains and losses on securities were primarily due to changes in interest rates. There are no investments in a continuous unrealized loss position for more than twelve months as of June 30, 2026. The Company does not intend to sell securities that are in an unrealized loss.

Common stock (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended		3 Months Ended	6 Months Ended
	Jun. 25, 2026	Aug. 31, 2025	Jan. 31, 2025	Jun. 30, 2026	Jun. 30, 2026
Capital Unit
Stock issuance costs				$ 400
Jefferies LLC \| Shelf Registration
Capital Unit
Shares issued and sold (in shares)	13,495,277
Net proceeds from company offering	$ 93,600
Common stock (in dollars per share)	$ 7.41
TD Securities (USA) LLC \| ATM Offering Program
Capital Unit
Sale of stock, maximum offering price		$ 100,000
Sale of stock, commission (as a percent)		3.00%
Cowen and Company L L C \| ATM Offering Program
Capital Unit
Shares issued and sold (in shares)					3,662,246
Net proceeds from company offering					$ 12,500
Advanced Micro Devices, Inc \| Private Placement
Capital Unit
Shares issued and sold (in shares)			5,714,285
Net proceeds from company offering			$ 20,000
Stock issuance costs			$ 2,500
Amortization of the premium					$ 400

Stock-based compensation - Restricted Stock (Details) - Restricted stock units	6 Months Ended
	Jun. 30, 2026 $ / shares shares
Nonvested, Number of Shares
Beginning balance, unvested (in shares) \| shares	3,789,634
Granted (in shares) \| shares	2,179,050
Vested (in shares) \| shares	(934,358)
Forfeitures (in shares) \| shares	(529,658)
Ending balance, unvested (in shares) \| shares	4,504,668
Weighted Average Grant Date Fair Value
Beginning balance unvested (in usd per share) \| $ / shares	$ 3.32
Granted (in usd per share) \| $ / shares	3.02
Vested (in usd per share) \| $ / shares	3.49
Forfeitures (in usd per share) \| $ / shares	2.91
Ending balance unvested (in usd per share) \| $ / shares	$ 3.18

Fair value measurements

6 Months Ended

Jun. 30, 2026

Fair Value Disclosures [Abstract]

Fair value measurements

The Financial Accounting Standards Board (“FASB”) has defined fair value to establish a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such

assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1: Observable inputs such as quoted prices in active markets.

Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

When quoted market prices are available in active markets, the fair value of assets and liabilities is estimated within Level 1 of the valuation hierarchy.

If quoted prices are not available, then fair values are estimated by using pricing models, quoted prices of assets and liabilities with similar characteristics, or discounted cash flows, within Level 2 of the valuation hierarchy. In cases where Level 1 or Level 2 inputs are not available, the fair values are estimated by using inputs within Level 3 of the hierarchy.

The following tables summarize the Company’s assets and liabilities measured at fair value on a recurring basis as of June 30, 2026 and December 31, 2025 (in thousands):



	June 30, 2026
	Level 1		Level 2		Level 3		Total
Assets:
Debt Securities:
Money market funds	$	98,399	$	—	$	—	$	98,399

U.S. treasuries	—		93,277		—		93,277


Total assets	$	98,399	$	93,277	$	—	$	191,676



	December 31, 2025
	Level 1		Level 2		Level 3		Total
Assets
Debt Securities:
Money market funds	$	14,410	$	—	$	—	$	14,410

U.S. treasuries	6,873		117,394		—		124,267


Total assets	$	21,283	$	117,394	$	—	$	138,677

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details